Page last updated: 2024-11-12
diosgenin glucoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
diosgenin glucoside: RN given refers to (3beta,25R)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
diosgenin 3-O-beta-D-glucoside : A sterol 3-beta-D-glucoside having diosgenin as the sterol component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11827970 |
| CHEMBL ID | 395414 |
| CHEBI ID | 74020 |
| SCHEMBL ID | 2734312 |
| MeSH ID | M0147760 |
Synonyms (48)
| Synonym |
|---|
| trillin |
| AC-11225 |
| 14144-06-0 |
| disogluside |
| CHEMBL395414 |
| chebi:74020 , |
| bdbm50021400 |
| collettiside i |
| (25r)-3beta-(beta-d-glucopyranosyloxy)spirost-5-ene |
| disoglusidum |
| unii-8ki671f2ns |
| diosgenin glucoside |
| disogluside [inn] |
| disoglusido [inn-spanish] |
| disoglusido |
| 8ki671f2ns , |
| disoglusidum [inn-latin] |
| S9068 |
| AKOS015960440 |
| (25r)-spirost-5-en-3beta-ol 3-o-beta-d-glucopyranoside |
| (3beta,25r)-spirost-5-en-3-yl beta-d-glucopyranoside |
| diosgenin 3-o-beta-d-glucoside |
| (25r)-spirost-5-en-3beta-yl beta-d-glucopyranoside |
| 3-o-(glcbeta)-(25r)-spirost-5en-3beta-ol |
| diosgenin 3-beta-d-glucoside |
| 1h-pyrrole-2,4-dicarboxylicacid, 3,5-dimethyl- |
| SCHEMBL2734312 |
| C20709 |
| (3beta,25r)-spirost-5-en-3-ol 3-o-beta-d-glucopyranoside |
| diosgenin 3-o-beta-d-glucopyranoside |
| b-d-glucopyranoside, (3b,25r)-spirost-5-en-3-yl |
| AC-34930 |
| Q-100152 |
| diosgenin-glucoside |
| 3-o-beta-d-glc-diosgenin |
| diosgeninglucoside |
| diosgenin 3-glucoside |
| collettinside i |
| prosapogenin d'3 |
| melongoside b |
| funkioside a |
| Q27144338 |
| (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(1s,2s,4s,5'r,6r,7s,8r,9s,12s,13r,16s)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxyoxane-3,4,5-triol |
| CCG-270115 |
| CS-0009743 |
| HY-N0730 |
| A885676 |
| MS-30378 |
Research Excerpts
Overview
Diosgenin glucoside (Dios) is a saponin compound extracted from Tritulus terrestris L.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Diosgenin glucoside (Dios) is a saponin compound extracted from Tritulus terrestris L." | ( Diosgenin glucoside provides neuroprotection by regulating microglial M1 polarization. Guo, H; Hu, L; Li, R; Wang, F; Wang, S; Yang, H, 2017) | 2.62 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Diosgenin was modified to control its in vivo bioavailability by conjugating a hydrophilic unit, tetraethylene glycol." | ( Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. Hong, BN; Hong, HN; Kang, TH; Kim, DH; Kim, TW; Le, HT; Lim, CW; Park, KH, 2012) | 0.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (4)
| Class | Description |
|---|---|
| sterol 3-beta-D-glucoside | Any beta-D-glucoside derived from a sterol. |
| monosaccharide derivative | A carbohydrate derivative that is formally obtained from a monosaccharide. |
| hexacyclic triterpenoid | A triterpenoid that consists of a hexacyclic ring system. |
| spiroketal | A cyclic ketal in which the ketal carbon is the only common atom of two rings. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Interleukin-2 | Homo sapiens (human) | Kd | 0.0000 | 0.0000 | 1.3037 | 5.4700 | AID1156797 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (38)
Molecular Functions (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytokine activity | Interleukin-2 | Homo sapiens (human) |
| interleukin-2 receptor binding | Interleukin-2 | Homo sapiens (human) |
| protein binding | Interleukin-2 | Homo sapiens (human) |
| growth factor activity | Interleukin-2 | Homo sapiens (human) |
| kinase activator activity | Interleukin-2 | Homo sapiens (human) |
| carbohydrate binding | Interleukin-2 | Homo sapiens (human) |
| kappa-type opioid receptor binding | Interleukin-2 | Homo sapiens (human) |
| glycosphingolipid binding | Interleukin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (2)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Interleukin-2 | Homo sapiens (human) |
| extracellular region | Interleukin-2 | Homo sapiens (human) |
| extracellular space | Interleukin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (16)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID672435 | Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in body weight at 20 mg/kg, po administered QD measured 9 weeks after STZ challenge (Rvb = 34.15 +/- 1.16 g) | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID672436 | Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 10 mg/kg, po administered QD measured 1 week after STZ challenge (Rvb = 516.33 +/- 46.73 mg/dl) | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID294375 | Cytotoxicity against human erythrocytes assessed as hemolytic activity after 60 mins | 2007 | Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7 | Exploration of the correlation between the structure, hemolytic activity, and cytotoxicity of steroid saponins. |
| AID672437 | Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 10 mg/kg, po administered QD measured 9 weeks after STZ challenge (Rvb = 529.90 +/- 49.17 mg/dl) | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID672443 | Protective activity against hearing loss in streptozotocin-induced diabetic ICR mouse using 8 KHz tone bursts at 20 mg/kg, po administered QD measured after 8 weeks by auditory brainstem response test | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID672439 | Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 20 mg/kg, po administered QD measured 9 weeks after STZ challenge (Rvb = 529.90 +/- 49.17 mg/dl) | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID672445 | Protective activity against hearing loss in streptozotocin-induced diabetic ICR mouse assessed as decrease in positive A peak latency at 20 mg/kg, po administered QD measured after 8 weeks by auditory middle latency response test | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID294370 | Cytotoxicity against human erythrocytes assessed as hemolytic activity at 100 ug/ml after 60 mins | 2007 | Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7 | Exploration of the correlation between the structure, hemolytic activity, and cytotoxicity of steroid saponins. |
| AID1156799 | Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking. |
| AID672434 | Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in body weight at 20 mg/kg, po administered QD measured 1 week after STZ challenge (Rvb = 33.25 +/- 0.75 g) | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID672433 | Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in body weight at 10 mg/kg, po administered QD measured 9 weeks after STZ challenge (Rvb = 34.15 +/- 1.16 g) | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID672447 | Protective activity against hearing loss in streptozotocin-induced diabetic ICR mouse assessed as increase in negative A peak-positive A peak amplitude at 20 mg/kg, po administered QD measured after 8 weeks by auditory middle latency response test | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID672442 | Protective activity against hearing loss in streptozotocin-induced diabetic ICR mouse using 4 KHz tone bursts at 20 mg/kg, po administered QD measured after 8 weeks by auditory brainstem response test | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID672438 | Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 20 mg/kg, po administered QD measured 1 week after STZ challenge (Rvb = 516.33 +/- 46.73 mg/dl) | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| AID1156797 | Binding affinity to IL-2 (unknown origin) | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking. |
| AID672432 | Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in body weight at 10 mg/kg, po administered QD measured 1 week after STZ challenge (Rvb = 33.25 +/- 0.75 g) | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.89
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.89) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||